Dr. DeVincenzo Studies Respiratory Syncytial Virus (RSV)

Written by Communications and Marketing

| October 27, 2014

John DeVincenzo, MD, of the department of pediatrics at the University of Tennessee Health Science Center in Memphis, Tenn., said the current double blind, placebo-controlled phase 2 study aimed to evaluate ALS‑008176, an oral nucleoside analogue that causes nascent RNA chain-termination, thereby inhibiting RSV replication.

Related